Risk of venous thromboembolism in carriers of factor V Leiden with a concomitant inherited thrombophilic defect:: a retrospective analysis

被引:24
|
作者
Meinardi, JR
Middeldorp, S
de Kam, PJ
Koopman, AMW
van Pampus, ECM
Hamulyák, K
Prins, MH
Büller, HR
van der Meer, J
机构
[1] Univ Hosp, Div Haemostasis Thrombosis & Rheol, NL-9713 GZ Groningen, Netherlands
[2] Univ Hosp, Trial Coordinat Ctr, Groningen, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Ctr Haemostasis Thrombosis Atherosclerosis & Infl, NL-1105 AZ Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands
[5] Univ Hosp, Dept Haematol, Maastricht, Netherlands
关键词
thromboembolism; blood coagulation disorders; activated protein C resistance; factor V;
D O I
10.1097/00001721-200112000-00014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Factor V Leiden is the most common genetic defect associated with venous thromboembolism. Its clinical expression is limited and shows a wide intrafamilial and interfamilial variation, which might be explained by the influence of other genetic risk factors. We retrospectively studied 226 patients with factor V Leiden and documented venous thromboembolism (probands) and 400 first-degree carrier relatives to assess the contribution of concomitant genetic risk factors to the occurrence of venous thromboembolism. The prothrombin G20210A mutation was found in 8.3%, homozygosity of factor V Leiden in 7.2%, and inherited deficiencies of antithrombin, protein C or protein S in 4.7% of symptomatic carriers (probands and relatives), as compared with 6.0, 3.4 and 0.9% of asymptomatic carriers, respectively. The total follow-up time in relatives was 11049 years. Prevalences of venous thromboembolism were 10.8% in single heterozygous factor V Leiden carrier relatives, 16.0% in double-heterozygotes for factor V Leiden and the prothrombin mutation, 36.8% in homozygotes for factor V Leiden, and 40.0% in double-heterozygotes for factor V Leiden and an inherited deficiency of protein C or protein S. Annual incidences in these groups were 0.39, 0.57, 1.41, and 4.76%, respectively. Multivariate analysis showed a small, non-significant additional effect of the prothrombin mutation on the risk of venous thromboembolism in heterozygotes for factor V Leiden [adjusted hazard ratio, 1.3; 95% confidence interval (CI), 0.5-3.8]. This effect was more pronounced for homozygosity of factor V Leiden (adjusted hazard ratio, 3.9; 95% CI, 1.7-9.0) and inherited protein C or protein S deficiencies (adjusted hazard ratio, 17.5; 95% CI, 3.8-81.2). Our data provide evidence of clustering of the evaluated genetic thrombophilic defects in symptomatic factor V Leiden carriers and support the assumption that the clinical expression of factor V Leiden depends on clustering in a part of carriers. Blood Coagul Fibrinolysis 12:713-720 (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:713 / 720
页数:8
相关论文
共 50 条
  • [21] The risk of recurrent venous thromboembolism in patients with and without factor V Leiden
    Eichinger, S
    Pabinger, I
    Stumpflen, A
    Hirschl, M
    Bialonczyk, C
    Schneider, B
    Mannhalter, C
    Minar, E
    Lechner, K
    Kyrle, PA
    THROMBOSIS AND HAEMOSTASIS, 1997, 77 (04) : 624 - 628
  • [22] Family History of Venous Thromboembolism and Identifying Factor V Leiden Carriers During Pregnancy
    Horton, Amanda L.
    Momirova, Valerija
    Dizon-Townson, Donna
    Wenstrom, Katharine
    Wendel, George
    Samuels, Philip
    Sibai, Baha
    Spong, Catherine Y.
    Cotroneo, Margaret
    Sorokin, Yoram
    Miodovnik, Menachem
    O'Sullivan, Mary J.
    Conway, Deborah
    Wapner, Ronald J.
    OBSTETRICS AND GYNECOLOGY, 2010, 115 (03): : 521 - 525
  • [23] Risk factors for venous thromboembolism in 202 women carriers of factor V Leiden mutation and oral contraceptive users
    Desmarais, S
    Conard, J
    PluBureau, G
    Horellou, MH
    Elalamy, I
    Samama, MM
    THROMBOSIS AND HAEMOSTASIS, 1997, : S1525 - S1525
  • [24] Risk of venous thromboembolism during pregnancy in homozygous carriers of the factor V Leiden mutation:: Are there any predictive factors?
    Biron-Andréani, C
    Daurès, JP
    Schved, JF
    Morange, P
    Aillaud, MF
    Juhan, I
    Lecam-Duchez, V
    Saladin-Théron, C
    Borg, JY
    Bauters, A
    Jude, B
    Denninger, MH
    Pernod, G
    Polack, B
    de Prost, D
    Delahousse, B
    Fimbel, B
    Gruel, Y
    Vergnes, C
    Voisin, S
    Trossaërt, M
    Vollot, F
    Dutrillaux, F
    Lorenzini, JL
    Lequerrec, A
    Boinot, C
    Freyburger, G
    Berruyer, M
    Trzeciak, MC
    Deschamps, A
    Favier, R
    BLOOD, 2002, 100 (11) : 271A - 271A
  • [25] Risk of venous thromboembolism during pregnancy in homozygous carriers of the factor V Leiden mutation:: are there any predictive factors?
    Biron-Andréani, C
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (02) : 359 - 360
  • [26] THROMBOELASTOGRAM IN CARRIERS OF THROMBOPHILIC MUTATIONS OF PROTHROMBIN (FII) AND FACTOR V LEIDEN
    Pizzuti, M.
    Adurno, G.
    Calabrese, A.
    Dragonetti, D.
    Coluzzi, S.
    Pascale, S. P.
    Nuccorini, R.
    Matturro, A.
    Amendola, A.
    Filardi, N.
    Cimminiello, M.
    Attolico, I.
    Vertone, D.
    HAEMATOLOGICA, 2016, 101 : S87 - S87
  • [27] Inherited thrombophilic risk factors and different clinical manifestations of venous thromboembolism
    Margaglione, M
    Brancaccio, V
    Martinelli, I
    De Lucia, D
    Ciampa, A
    Cianfrone, N
    Grilli, M
    D'Andrea, G
    del Popolo, A
    Santacroce, R
    Grandone, E
    Di Minno, G
    Rotondo, SG
    Cardarelli, A
    Bonomi, AB
    THROMBOSIS AND HAEMOSTASIS, 1999, : 371 - 371
  • [28] EVALUATION OF FACTOR V LEIDEN VARIANT AS RISK A FACTOR FOR VENOUS THROMBOEMBOLISM IN GLIOBLASTOMA PATIENTS
    Heenkenda, M.
    Lysiak, M.
    Akesson, L.
    Milos, P.
    Mudaisi, M.
    Bratthall, C.
    Strandeus, M.
    Soderkvist, P.
    Uppugunduri, S.
    Osman, A.
    Malmstrom, A.
    NEURO-ONCOLOGY, 2018, 20 : 267 - 267
  • [29] Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden - Cost-effectiveness analysis
    Marchetti, M
    Pistorio, A
    Barosi, G
    THROMBOSIS AND HAEMOSTASIS, 2000, 84 (05) : 752 - 757
  • [30] Venous thromboembolism and factor V Leiden: Enigma or paradox
    Gabriel, Francisco
    Portoles, Olga
    Labios, Manuel
    Rodriguez, C.
    Cisneros, E.
    Vela, J. R.
    Nunez, M. J.
    THROMBOSIS RESEARCH, 2012, 130 : S133 - S134